Home > News > Content

FDA Strengthens Warning On Opioid Cough And Cold Medicines

- Jan 13, 2018 -

FIG1 opioid cough and cold medicines.jpg

Recently, the FDA has announced that it's requiring revisions to the safety labeling on such prescription opioid cough and cold medicines to indicate that the products no longer can be used to treat children -- because their risks outweigh their potential benefits -- and should be used only for adults 18 and older.

Labeling changes also address safety information for adults, including an expanded boxed warning indicating the risks of using opioid medications, such as misuse, abuse, addiction, overdose and death.

The revised safety warnings on these products will be consistent with the labeling of other opioid-containing drug products, such as immediate-release opioid analgesics and extended-release and long-acting opioid analgesics, according to the FDA.

"Given the epidemic of opioid addiction, we're concerned about unnecessary exposure to opioids, especially in young children. We know that any exposure to opioid drugs can lead to future addiction," FDA Commissioner Dr. Scott Gottlieb said in an announcement on the FDA's website.

In 2013, the FDA issued a public warning and implemented a "black box warning" -- the strongest safety statement -- against prescribing codeine to children for pain management after having their tonsils or adenoids surgically removed.

Though the FDA's warning substantially decreased codeine prescriptions among children after tonsillectomies or adenoidectomies, about one in 20 kids undergoing those surgeries still was prescribed codeine in December 2015, despite safety concerns and efficacy issues, according to a study published in the journal Pediatrics in November.

FIG2 opioid cough and cold medicines.jpg

The study included data on 362,992 privately insured children who had undergone those surgical procedures.

In 2015, the FDA also announced an investigation into the possible risks of using codeine-containing medicines to treat coughs and colds in children under 18.

Then, last year, the agency warned that the opioids codeine and tramadol could cause life-threatening breathing problems in children and strengthened drug labeling to restrict their use in children younger than 12.

The FDA also recommended against the use of these medications by women who are breastfeeding.

Gottlieb said in a statement in August that the FDA would be meeting with the Pediatric Advisory Committee to further evaluate the use of prescription opioid products containing hydrocodone or codeine to treat cough in children.

Now, the FDA's latest action to revise safety labeling on some prescription cough and cold products expands the pediatric restrictions that were previously in place.

Parents whose children are currently prescribed a cough and cold medicine containing codeine or hydrocodone are encouraged to talk to their child's health care professional about other treatment options, the FDA advised.

Related News

Related Products

  • Water Soluble Ultrafine Spirulina Powder Colorant
  • Natural Blue Pigment Spirulina Extract Powder Healthy Food Colorant
  • Liquid Spirulina Extract Blue Food Colorant
  • Natural Blue Phycocyanin for Cosmetic Additive
  • High Protein Beverage Additive Natural Nutrition
  • Phycobiliprotein Blue Spirulina Extract Powder